Cisplatin-based chemotherapy is the paradigm of non-smallcell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (Po0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (Po0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment.
Introduction
Non-small-cell lung cancer (NSCLC) comprises more than 80% of lung cancers, with 1.2 million new cases worldwide each year (WCR, 2003; Jemal et al., 2008) . Cisplatin (CDDP)-based chemotherapy remains the standard treatment in combination with other chemotherapeutic agents; however, NSCLC patients frequently exhibit chemotherapy resistance. Molecular mechanisms of drug resistance remain unclear and are believed to be multifactorial, involving host factors, numerous molecular events and genetic and epigenetic changes (Gottesman, 2002) . In addition, chemotherapeutics induce epigenetic changes in the promoter area of specific genes, altering expression and possibly underlying resistance in many tumor types (Baker et al., 2005) .
The aberrant DNA hypermethylation of CpG islands in the gene promoter region is well-described as an alternative mechanism for tumor suppressor genes silencing in cancer cells. This includes lung cancer cells, in which MGMT, p16, RARb, TIMP-3 and DAPK have been reported as hypermethylated (Merlo et al., 1995; Esteller et al., 1999; Zochbauer-Muller et al., 2001) . In addition, drug-induced DNA hypermethylation could be a mechanism of tumor cell response to chemotherapy agents (Nyce, 1997; Strathdee et al., 1999; Shen et al., 2004; Zhang et al., 2004) . In both lung adenocarcinoma (HTB-54) and rhabdomyosarcoma human cells , pulse exposure to CDDP is associated with drug-induced DNA hypermethylation (Nyce, 1989) , an event that has also been reported in vivo (Koul et al., 2004) . Therefore, one possible reason for the development of chemoresistance in NSCLC might be the epigenetic inactivation of certain tumor suppressor gene as a consequence of chemotherapy treatment. This epigenetic silencing could be reverted by demethylating drugs and histone deacetylase inhibitors such as 5 Aza-2deoxycytidine (5Aza-dC) and Trichostatine A (TSA). Both drugs act in synergy by depleting methyltransferase activity (Baylin et al., 1998) and reversing the formation of transcriptionally repressive chromatin structure (Marks et al., 2004) . Thus, the association between promoter-demethylation of hMLH1 by pharmacological treatment and reversal of drug-resistance has been reported in human tumor xenografts (Plumb et al., 2000; Steele et al., 2009) .
Many epigenetically silenced tumor suppressor gene involved in cancer-chemoresistance likely remain to be identified as most studies have focused on a limited number of candidate genes (Strathdee et al., 1999; Shen et al., 2004) . Therefore, a microarray-based screening pairing the differential genetic profile of sensitive and CDDP-resistant cell lines with an epigenetic reactivation approach has the advantage of a global analysis that should preferentially identify epigenetically silenced genes as a result of acquired CDDP-chemoresistance.
In this study, we first established two CDDP-resistant cell lines derived from the sensitive H23 and H460 NSCLC cell lines. Screening for genes differentially expressed in those resistant cells compared with their drug-sensitive parent cells and re-expressed after 5Aza-dC and TSA treatments is a new approach that can provide signatures for the identification of target genes for chemotherapy profiling. This process may lead to further elucidation of the biology of treatment response in NSCLC. We have identified a panel of genes showing this pattern, and found the insulin-like growth factorbindin protein-3 (IGFBP-3) gene specifically downregulated through promoter-hypermethylation in the resistant phenotypes.
The biological significance of IGFBP-3 is of great importance in controlling cell growth, transformation and survival. It is the main IGFBP-family member, physiologically, IGFBP-3 binds IGF-I with stronger affinity than the specific IGF-I receptor (IGFI-R) to the cell membrane, blocking their interaction and, therefore, the IGF-I mitogenic and anti-apoptotic actions. It is induced by wild-type p53 and interacts with the TGF-b and EGFR pathways (Buckbinder et al., 1995; Rajah et al., 1997; Guix et al., 2008) . IGFBP-3 has been recently reported by the authors and others as a candidate tumor suppressor gene under epigenetic regulation in several tumor types including lung, kidney and ovarian cancer (Chang et al., 2002b; Ibanez de Caceres et al., 2006; Wiley et al., 2006) , and although its role in tumor progression has been studied, its function in acquired resistance to CDDP, chemotherapy response prediction as well as in drugresistance phenotype identification remains to be characterized. In this study we examined the promoter methylation profile of IGFBP-3 regarding sensitivity to CDDP in 27 human cancer cell lines and in a panel of 36 NSCLC specimens. We report that a loss of IGFBP-3 expression mediated by aberrant promoter hypermethylation results in a reduction of tumor cell sensitivity to CDDP treatment in NSCLC.
Results

Establishment of NSCLC human cell lines resistant to CDDP
We established two human NSCLC cell lines resistant to CDDP, H23R and H460R, which were selected after a final exposure to 0.2 and 0.5 mg/ml CDDP respectively, showing approximately four times more drug resistance than the matched parental cell line (4.07 and 3.89 resistant index; Po0.001 and Po0.002) (Supplementary  Figures 2a, b and c) . Both cell lines showed a similar CDDP resistant-index to 41R ovarian cancer cells (4.8; Po0.001) (Supplementary Figure 2c) .
Identification of genes induced by 5Aza-dC and TSA treatment in CDDP-resistant cell lines We identified a group of genes under direct or indirect regulation of 5Aza-dC and TSA that were involved in important tumor-related pathways, including cell growth, apoptosis and negative regulation of cell-cycle progression. It is interesting to note that only three genes were commonly re-expressed in both cell lines at similar levels to the sensitive parental cells. We also selected a second group of six genes specifically re-expressed in each cell line, representing, as expected, significant inter-individual variation in drug response ( Figure 1a) .
For gene validation, we first tested their expression profile by RT-PCR, confirming the results from microarray analyses in all nine genes analyzed. The expression of ARRDC-4, DKK1 and DUSP5 was dramatically decreased in both H23R and H460R cell lines compared with their parental line, whereas a strong signal in H23R-T and H460R-T cells confirmed reexpression after 5Aza-dC and TSA treatment. AREG, GDF-15 and IGFBP-3 followed the same pattern in H23 cells, whereas NNAT, PHLDA1 and S100A2 did in H460 cells (Figure 1b) . We previously reported that GDF-15 was methylated in normal tissues (Ibanez de Caceres et al., 2006) ; therefore, we next used bisulfite sequencing (BS) to validate the promoter-methylation status in the remaining genes containing a real CpG island. Promoters of ARRDC4, DKK1, DUSP5, AREG and PHLDA1 were unmethylated in all experimental groups, indicating that they are not under direct epigenetic regulation, as an example, the methylation status of ARRDC4 is shown in Figure 1c . The NNAT gene was methylated in DNA from non-neoplastic lung, H460 and H460R cells, suggesting possible epigenetic regulation that could explain the intense signal in H460R cells after reactivation treatment. Data from DKK1, DUSP5, AREG, PHLDA1 and NNAT are shown in Supplementary Figure 3. IGFBP-3 CpG-island study and methylation analysis For IGFBP-3, we studied a promoter CpG island located À518/ þ 744 from the first exon, where we examined the 688 bp upstream from the ATG site. The island was unmethylated in non-neoplastic lung tissue DNA, whereas H23R resistant-cells were more densely methylated than H23S, in accordance with the decrease observed in gene expression. In addition, re-activation treatment restored unmethylated promoter and gene expression in H23R (Figure 2) . We used the matched 41S and 41R cells to verify that IGFBP-3-methylation status was directly related with the CDDP-resistance process, as ovarian cancer is, like NSCLC, a tumor type that exhibits frequent resistance after CDDP-based therapy. Supporting our results, we found the IGFBP-3 promoter completely unmethylated in 41S cells and densely methylated in 41R cells, whereas 5-Aza-dC/TSA treatment again restored promoter unmethylation and gene expression, confirming that IGFBP-3-hypermethylation occurs in those cells as a CDDP resistance-specific process. Furthermore, using qRT-PCR, we confirmed that IGFBP-3 expression was 1000-fold higher in 41S cells than in H23S cells, in which the IGFBP-3 promoter is semimethylated (Supplementary Figure 4) . Accordingly, we established that IGFBP-3-methylation in 41R cells parallels a decrease in gene expression of more than 10 000-fold compared with 41S cells (Supplementary Figure 4) , whereas reactivation treatment increased the expression by 10 times. These results indicate that hypermethylation of IGFBP-3 is specific to CDDP-resistant cell lines.
IGFBP-3-promoter methylation mediates the response to CDDP To investigate if IGFBP-3-promoter hypermethylation mediates chemosensitivity to CDDP or is a consequence of treatment, we silenced expression in 41S cells, as in these cells IGFBP-3 is highly expressed and therefore susceptible to being successfully knocked-down. Transfection of the siRNA-negative-control did not affect the IGFBP-3 expression pattern in 41R and 41S cells (Figure 3a) . IGFBP-3 expression was successfully silenced in 41S cells with 75% interference efficiency 24 h after transfection, effect that was maintained after 72 h with an approximately 70% efficiency compared with 41S cells transfected with control-RNAi (Figure 3b ). This IGFBP-3 silencing induced a decrease in CDDP sensitivity compared with cells transfected with the negative control, resulting in a significant increase in the IC 50 value in response to CDDP (0.5 mg/ ml vs 0.3 mg/ml, Po0.001). Those cells showed an intermediate sensitivity degree between 41S and 41R cells transfected with the negative control, with a resistance index lower than 41R RNAi NC cells (1.67 vs 4.1, Po0.001), in which IGFBP-3 is completely silenced by promoter methylation (Figures 3c and d) . These results confirm IGFBP-3 promoter hypermethylation as an event that mediates the response to CDDP.
Next, CDDP viability response and IGFBP-3 methylation status were measured in 23 additional cancer cell IGFBP-3-methylation as a chemo-resistance biomarker I Ibanez de Caceres et al lines, in order to study the correlation between promoter hypermethylation and CDDP-resistance, and to confirm the most frequent methylation positions for the methylation-specific PCR (MSP) primer design (Supplementary Table 1) . Results showed different viability responses to CDDP independently of tumor type. In all, 16 out of 23 (70%) cell lines showed low CDDPsensitivity (IC 50 42.5 mg/ml), with IGFBP-3 methylated in 12 (75%), probably as a consequence of metastasic origin of cell lines (Supplementary Figure 1) . The MSP primers designed by comparing the BS from the cell lines were used to analyze the IGFBP-3-methylation status in DNA from the formalin-fixed, paraffin-embedded-NSCLC tumors, as described below.
Specific methylation of IGFBP-3 in CDDP-resistant NSCLC primary tumors
To determine whether IGFBP-3 methylation is a frequent event in primary tumors that correlates with the response to CDDP, we exposed 36 stage I/II NSCLC fresh tumors to various CDDP concentrations, analyzed their IGFBP-3-methylation status by MSP and studied their correlation with clinical history. All baseline characteristics vs CDDP-sensitivity and methylation status are summarized in Table 1 , whereas individual patient data are listed in Supplementary Table 2. According to receiver operating characteristic methodology, the IC 50 index clearly delineated two groups of patients in terms of the sensitive or resistant profile to CDDP. The cut-off point was established on an IC 50 of 7.5 mg/ml. Under these conditions, 19 out of the 36 samples were above this cut-off, and therefore, considered to have low sensitivity to CDDP, whereas 17 samples out of 36 were under this cut-off and considered highly sensitive. IGFBP-3 was more frequently methylated in resistant (14 out of 19, 74%) than in sensitive tumors (2 out of 17, 12%) (Po0.001); in addition, IGFBP-3 was unmethylated in 15 out of the 17 (88%) highly sensitive samples ( Figure 4c and Table 1 ). Consequently, we found an 81% (29 out of 36 samples) correlation between IGFBP-3-methylation status and response to CDDP (Figure 4c ). In addition, we did not detect any CpG-site methylation in ten additional nonneoplastic lung samples. DNA extracted from three fresh samples was used to test IGFBP-3-methylation as an internal control for the MSP analysis (Figure 4b ). An MSP sample is shown in Figure 4a ; patients 22 and 34 are unmethylated, whereas 19, 6 and 30 are methylated, linking with the BS shown in Figure 4b .
When comparing data from pooled patients according to stage and methylation status of the IGFBP-3-promoter, we observed that patients diagnosed with pathological stage I, whose tumors harbor an unmethylated promoter, had a clearly increased DFS compared with methylated stage I patients. In addition, a clear trend of unmethylated stage I patients towards higher IGFBP-3-methylation as a chemo-resistance biomarker I Ibanez de Caceres et al survival was evident in all strata (Figure 5b ), but without statistical significance, mainly because of a small sample size (Figure 5a) . Surprisingly, for stage II patients we observed the opposite scenario: patients that harbor an unmethylated promoter had a lower DFS than those methylated within the same stage. 
Discussion
A central issue to better understanding the natural history of NSCLC is why disease becomes refractory to CDDP-based chemotherapy treatment. Cisplatin has extensive antitumoral activity, whereas its toxicity in normal tissues is relatively restricted to specific cellular types such as gastrointestinal enterochromaffin cells, kidney convoluted tubules or dorsal root ganglia (McKeage, 1995) , suggesting an epigenetic influence in toxicity. In addition, CDDP exposure is associated with drug-induced DNA hypermethylation in vitro (Nyce, 1989) and clinically (Koul et al., 2004) , indicating the importance of epigenetic changes in the rapid induction of resistance. Most studies involving epigenetic chemotherapyacquired resistance have focused on a limited number of candidate genes, such as p16 (Katsaros et al., 2004) , RASSF1A (Yoon et al., 2001; Makarla et al., 2005) or hMLH1 (Strathdee et al., 1999) , which possibly contribute to resistance in ovarian, lung and other cancers. Here, we developed a microarray-based strategy to identify new potential targets of promoter hypermethylation in CDDP-resistant phenotypes in lung cancer, which are therefore potentially involved in the development of resistance. We established the cell lines H23R and H460R, with a CDDP-resistant index in accordance with the previously established cancer cell line 41R, assuming that similar resistant events could follow. NSCLC-resistant cell lines underwent epigenetic treatment, and were then compared with the parental and resistant cell lines through microarray assays. The ontology analysis identified a set of genes involved in several tumor progression pathways, similarly to a recently published genomic approach that identified apoptosis as one of the most represented IGFBP-3-methylation as a chemo-resistance biomarker I Ibanez de Caceres et al pathways associated with CDDP-resistance (Riedel et al., 2008) . From the nine genes selected for further validation, three were commonly re-expressed in both resistant cell lines, whereas six other genes were specific for each cell line, indicating that CDDP and 5Aza-dC/TSA treatments affect different groups of genes and/or biological pathways, which could explain the high inter-individual variation in drug response described in lung cancer patients (Herbst et al., 2008) . Further validation confirmed that all genes had basal expression in the parental cells, which highlights their importance in maintaining the sensitive phenotype, as they lacked or strongly diminished their expression in resistance. Confirming the relevance of our approach to identifying 'resistance-inductor-genes', it is interesting to note that the decreased expression of DKK1 has been recently associated with acquired CDDP resistance in head and neck cancer (Gosepath et al., 2008) . Epigenetic validation revealed that only one gene from our panel, IGFBP-3, had specific promoter methylation in CDDP-resistance, thereby indicating that the remaining genes are not under direct epigenetic regulation although their reexpression after 5Aza-dC/TSA treatment confirms recent findings (Morris et al., 2008) . Those genes could be activated by an upstream regulatory gene or transcription factor whose expression was reactivated by demethylation, as is the reported case of gene TGM2, which is re-expressed in kidney cancer but epigenetically regulated upstream by RASSF1A (Ibanez de Caceres et al., 2006) .
We focused on the epigenetic regulation of IGFBP-3. Our results show IGFBP-3 strongly silenced by promoter hypermethylation in 41R and H23R-resistant cells in comparison with respective parental cells, with marked IGFBP-3-basal expression. In addition, demethylation treatment restored the unmethylated CpG positions as well as gene expression, thus confirming the epigenetic regulation of IGFBP-3 in CDDP-resistant cell lines. Moreover, IGFBP-3 was more highly expressed in the unmethylated cell line 41S than in H23 cells, which IGFBP-3-promoter is semi-methylated. Those results confirm the correlation between the decrease in IGFBP-3 expression regulated by promoter hypermethylation and the loss of CDDP sensitivity. Furthermore, we here report that the IGFBP-3-promoter hypermethylation event is responsible for and not a consequence of CDDP-acquired resistance. This is because silencing of IGFBP-3 expression in the 41S cells induced a strong decrease in CDDP sensitivity with a relative resistance index transitional to resistant 41R and sensitive 41S cells. We also tested the specificity of aberrant IGFBP-3-promoter methylation to detect CDDP sensitivity in primary tumors, and found that most of CpG dinucleotides were methylated in resistant but not in sensitive primary samples, indicating a significant correlation between IGFBP-3-methylation and CDDP chemosensitive-response. IGFBP-3 was methylated in some patients before clinical exposure to CDDP, suggesting a possible intrinsic resistance to the drug. In fact, a follow-up study of those patients after chemotherapy treatment showed that patients diagnosed with pathological stage I and harboring an unmethylated IGFBP-3 promoter had a clear trend towards higher survival, evident in all strata, compared with other groups. Our sample size was not large enough to demonstrate a statistically significant difference between all groups, but it is a starting point for future studies. The surprising results obtained from stage II patients are also size-limited, but it is possible that adjuvant therapy typically administered for stage II patients could have a role in observed differences within this stage. Unfortunately, we have no full data about adjuvant therapy administered in our set of patients.
From our results, we report that IGFBP-3-methylation could be a master key used for cell tumor IGFBP-3-methylation as a chemo-resistance biomarker I Ibanez de Caceres et al progression in conjunction with its biological functions. Induction of IGFBP-3 gene expression by wild-type p53 is associated with enhanced secretion of an active form of IGFBP-3 capable of inhibiting mitogenic signaling by the IGF-I (Buckbinder et al., 1995) . The CGH profile of cell lines 41S and 41R indicate no changes in chromosome 17, whereas p53 is located at (17p13) (LeylandJones et al., 1999) , indicating that IGFBP-3 promoter methylation at the p53 regulatory element could cause gene silencing resistant to p53 in those cell lines. The IGF-I signaling pathway could mediate chemotherapy resistance of NSCLC cells through the activation of Akt/mTOR-mediated synthesis of survival proteins, thus protecting NSCLC cells from apoptosis induced by several drugs, as reported previously with drugs that inhibit tyrosine-kinase receptors including EGFR or IGFIR (Morgillo et al., 2006 (Morgillo et al., , 2007 . Those authors suggest that resistance is caused by the activation of alternative cell survival signaling mechanisms, because those drugs do not inhibit proliferation at doses sufficient to suppress EGFR activation. In fact, we observed decreased expression of IGFBP-3 in chemoresistant cell lines, therefore a higher amount of IGF-I should be available to join its own receptor and strongly activate the IGFIR pathway, inducing survival and maintaining proliferation in CDDP-resistant cells. In addition, in a p53 and/or IGF-I-independent pathway, methylation could also be the mechanism responsible for inhibiting the apoptosis mediated by IGFBP-3 through the activation of the TGF-b receptor TbR-V, (Rajah et al., 1997; Huang and Huang, 2005) . IGFBP-3-methylation has been correlated with clinicopathological features indicative of poor prognosis in prostate and ovarian cancers (Wiley et al., 2006; Perry et al., 2007) and in the early stages of NSCLC patients (Chang et al., 2002a (Chang et al., , 2002b , likely indicating that those patients have intrinsic resistance to CDDP. However, we know that those patients with unmethylated IGFBP-3 in early stages could also progress towards a methylated promoter after CDDP treatment, thus showing acquired resistance. A follow-up study after chemotherapy treatment measuring aberrant IGFBP-3 methylation in tumor DNA circulating in body fluids such as blood, bronchioalveolar fluid or saliva could identify this situation when CDDP-resistant cells arise, providing a non-invasive test to predict chemotherapy resistance.
In this study, we report that IGFBP-3 has an inverse effect on the risk of NSCLC CDDP chemoresistance development. CDDP induces changes in IGFBP-3 expression mediated by the acquisition of promoter hypermethylation, which promotes resistance to CDDP through various biological pathways. Therefore, basal methylation status of the IGFBP-3 promoter before chemotherapy treatment may be a clinical biomarker predictor of the chemotherapy outcome of NSCLC patients, identifying those who are most likely to benefit from CDDP therapy. These results represent a new application of epigenetic cell control in chemotherapy resistance. This application involves the possible use of new highly sensitive and non-invasive tests based on the detection of aberrant methylation in tumor-circulating DNA (Carvalho et al., 2008) , as well as the use of agents that reverse epigenetic changes. These agents have shown promising results in a mouse model of lung carcinogenesis and are being tested in lung cancer patients (Belinsky et al., 2003) 
Materials and methods
Cell culture and viability to CDDP A total of 23 human cancer cell lines (Supplementary Figure  1) , representing nine different cancer types, were purchased from the ATCC (Manassas, VA, USA) or the ECACC (SigmaAldrich, Madrid, Spain) and cultured as recommended. The CDDP-resistant variants H23R and H460R were established following the methodology described previously (Plasencia et al., 2006) and further detailed in Supplementary Materials and Methods (Roninson, 2003; Chattopadhyay et al., 2006; Levina et al., 2008) . To validate the results obtained from the resistant cell lines established in our laboratory, we also used CDDP-sensitive and resistant ovarian cancer cell lines 41M and 41MR, hereafter called 41S and 41R respectively, kindly provided by Dr Lloyd R Kelland (UK), and maintained in DMEM supplemented with 10% FBS.
NSCLC clinical samples and data collection
Fresh and formalin-fixed, paraffin-embedded surgical specimens were obtained from 36 patients who had undergone a complete resection (R0) for a histologically confirmed, early NSCLC. All patients had both a perioperative PET-CT scan showing localized disease and a pathological confirmation of stage I/II. In addition, an age of 18 years or older, intraoperative mediastinal-node dissection for reliable mediastinal staging or biopsy of nodes at N3 without any evidence of disease was inclusion criteria. Stage III, any involvement of tracheobronchial angle nodes (station 10), mixed histological features and previous diagnosis of cancer within the last 5 years were exclusion criteria. Histological slides obtained from each block were reviewed by an expert pathologist (M Nistal) to confirm the diagnosis and to guarantee at least 90% tumoral content. A total of 10 samples obtained from pulmonary biopsies with non-neoplastic lung pathology were used as control tissues. Follow-up was carried out according to the criteria used in the Medical Oncology Division from the University Hospitals La Paz and 12 de Octubre, including clinical assessments and thorax CT every 3 months for 2 years and every 6 months thereafter. Clinical, pathological and radiological data were recorded by an independent observer at the H. La Paz and blinded for statistical analysis.
5Aza-2dC and TSA treatment 5Aza-dC and TSA (Sigma-Aldrich) were stored as 5 mM and 330 mM stock solutions, respectively. For re-expression studies, resistant cell lines H23R, H460R and 41R were split to low density and exposed to 5Aza-dC and TSA or to PBS and ethanol (mock cells) as described previously (Ibanez de Caceres et al., 2006) .
Oligonucleotide array hybridization and gene selection Parental H-23 and H-460 cell lines, derived CDDP-resistant cell lines and resistant cell lines treated with 5Aza-dC and TSA were used for the oligonucleotide array hybridization. Total RNA was isolated and purified as described (Ibanez de Caceres et al., 2006) and used for the microarray and RT-PCR analysis. The microarray assay was carried out using the Agilent gene expression platform 4X44 Whole Human Genome Oligo Microarray Kit, representing the 41 000 known genes and transcripts in the human genome. Sample amplification, labeling and scanning procedures followed the Agilent microarray protocol and are further described in Supplementary Materials and Methods.
Reverse transcription and qRT-PCR Semiquantitative and real-time RT-PCR assays were carried out in all the experimental groups. In all, 5 mg of total RNA was reverse transcribed using oligo (dT)24 primer and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For quantitative real-time RT-PCR analysis, the amount of 1 mg of total RNA was retrotranscribed by HighCapacity cDNA Archive Kit (Applied Biosystems, Madrid, Spain). Next, each cDNA sample was analyzed in triplicate using the ABI PRISM 7700 Sequence Detector (PE Applied Biosystems, Madrid, Spain). Real-time PCR was carried out using Taqman 
siRNA transfection
The 41S and 41R cell lines were transfected with 150 nM IGFBP-3 siRNA or negative control siRNA (HSS105266, Stealth Select RNAi and 2935-200, stealth RNAi Negative Control, Invitrogen, Barcelona, Spain) according to manufacturer directions. For the viability assay, cells were seeded in 24-well dishes at 50 000 cells per well 24 h after transfection with IGFBP-3 siRNA or siRNA control, then treated with six different doses of CDDP for an additional 48 h and stained following the method described previously (Chattopadhyay et al., 2006) . Cell viability was estimated relative to the density recorded over the same experimental group without drug exposure at same period of time (24 h following seeding of cells). Simultaneously, same experimental groups were seeded at 500 000 cells per plate and harvested at same incubation periods, 24 and 72 h after siRNA transfection, as a time-course to test by RT-PCR the preservation of siRNA effects on IGFBP-3 expression.
BS and methylation-specific PCR DNA from human cancer cell lines, NSCLC primary specimens and non-neoplastic lung tissues were isolated, bisulfite modified and then used for BS and MSP analysis as described (Ibanez de Caceres et al., 2006) . PCR settings and primer sequences for BS and MSP are listed in Supplementary Materials and Methods and Supplementary Table 1.
Culture and CDDP treatment of human cancer tissues To measure the sensitivity of the 36 primary NSCLC samples to CDDP, fresh tumors were minced, passed through a nylon mesh and enzyme disaggregated with collagenase type II and hyaluronidase in Dulbeco's modified Eagle's medium nutrient mixture F-12/Ham media (Sigma-Aldrich) with antibiotics. Cells were resuspended in 96-well microtiter plates followed by exposure to various concentrations of CDDP as described in Supplementary Materials and Methods.
Statistical analysis
Differentially expressed genes from the microarray analysis were selected using as a statistical method the t-test unpaired algorithm with Benjamini Hochberg as the FDR correction method for multiple testing corrections. Statistically significant (Po0.05 as adjusted P-value) genes were selected. Calculations were carried out using the gene expression analysis software GeneSpring (further details in Oligonucleotide array hybridization and gene selection from Supplementary Materials and Methods).
Receiver operating characteristic curves from NSCLC patients were obtained to identify the relation between sensitivity and resistance rate at a specific cut-off value established according to the best combination of sensitivity and false-positive rate (1-specificity) (1;0).
The Kaplan-Meier method was used to plot cumulative disease-free survival curves for patients diagnosed with stage I and unmethylated IGFBP-3 promoter, stage I methylated, stage II unmethylated and stage II methylated. Differences were compared with the log-rank method for every stratum. For patients without any evidence of relapse at the time of analysis, data on disease-free survival were censored at the time of last contact. Disease-free survival was defined as the time from surgery to clinical, radiological or histological evidence of relapse. Discrete variables (histology, T, N, stage, gender and methylation status at the IGFBP3 promoter and in vitro sensitivity/resistance to CDDP) were compared with the w 2 test and corrections with Fisher's exact test were made when needed. Statistical significance was defined as Po0.05. Statistical analyses were done by using the SPSS software (version 17.0).
